ABCL — AbCellera Biologics Inc. stock price, charts and financials

QT61AbCellera Biologics Inc.

AbCellera Biologics Inc. (NASDAQ: ABCL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.21
+2.28+32.83%
OverviewShort InterestFilings
ABCLQT61AbCellera Biologics Inc.·NASDAQ
9.21+32.83%
News
Up 32.8% — ABCL-635 Phase II trial cut menopause hot flashes 83%, demonstrating efficacy for a high-prevalence indication.
High confidence
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
STOK-0.83%$32.44VRDN-1.19%$23.31TSHA-0.38%$6.54GHRS-1.76%$29.74RAPP+1.77%$46.30ZBIO-0.43%$32.29MESO+5.02%$16.74NKTR-1.14%$75.61
Snapshot
Index-P/E-EPS (ttm)-0.48Insider Own-Shs Outstand305.38MPerf Week21.37%
Market Cap2.12BForward P/E-EPS next Y-0.63Insider Trans0.14%Shs Float205.09MPerf Month-4.94%
Enterprise Value2.13BPEG23.63EPS next Q-Inst Own-Short Float22.00%Perf Quarter43.78%
Income-164.64MP/S31.98EPS this Y-24.74%Inst Trans-Short Ratio5.65Perf Half Y149.28%
Sales66.17MP/B2.36EPS next Y-4.50%ROA-12.59%Short Interest45.11MPerf YTD102.63%
Book/sh-P/C-EPS next 5Y-ROE-17.49%52W High11.21 -17.89%Perf Year68.20%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-14.95%52W Low3.65 152.00%Perf 3Y-0.14%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-46.32% -20.28%Gross Margin74.95%Volatility8.99% 7.63%Perf 5Y-54.32%
Dividend TTM-EV/Sales32.22EPS Y/Y TTM12.73%Oper. Margin-340.25%ATR (14)0.51Perf 10Y-
Dividend Ex-Date-Quick Ratio12.63Sales Y/Y TTM172.41%Profit Margin-248.83%RSI (14)61.64Recom2.08
Dividend Gr. 3/5Y-Current Ratio12.77EPS Q/Q6.67%SMA2015.75%Beta1.19Target Price8.00
Payout0.00%Debt/Eq0.15Sales Q/Q100.00%SMA5011.97%Rel Volume0.88Prev Close6.93
Employees562LT Debt/Eq0.14EarningsNov 05SMA20054.23%Avg Volume7.23MPrice9.21
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.18.33% 53.63%Net Debt/EBITDA-0.10Volume6,363,245Change32.83%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedStifel Nicolaus$8.00 → $9.00
Jul-07-26UpgradeBenchmarkHold → Buy
May-12-26ReiteratedStifel Nicolaus$7.00 → $8.00
May-05-26InitiatedCantor FitzgeraldOverweight$7.00
Nov-07-25DowngradeLeerink PartnersOutperform → Market Perform
Nov-05-24ReiteratedBMO CapitalOutperform$5.00
Aug-23-24ReiteratedKeyBancOverweight$7.00 → $5.00
Aug-20-24DowngradeBenchmarkBuy → Hold
May-08-24ReiteratedKeybancOverweight$7.00
Feb-22-24UpgradeBenchmarkHold → Buy
Latest News
Today
Today09:04AM
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trialmarketbeat.com
Aug-07-26
Aug-07-2604:30PM
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026businesswire.com
Aug-06-26
Aug-06-2610:13AM
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9Benzinga
12:20AM
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-05-26
Aug-05-2609:36PM
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimateszacks.com
06:06PM
AbCellera Biologics Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
AbCellera Reports Q2 2026 Business Resultsbusinesswire.com
Jul-29-26
Jul-29-2607:06AM
Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.Benzinga
07:00AM
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditionsbusinesswire.com
Jul-23-26
Jul-23-2603:15PM
Playing The Biotech Breakout With Insidersseekingalpha.com
09:05AM
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbersprnewswire.com
Jul-21-26
Jul-21-2601:26PM
Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha
Jul-07-26
Jul-07-2604:05PM
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026businesswire.com
01:01PM
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choicezacks.com
07:50AM
Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price TargetBenzinga
Company

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue667529——————
Cost of Goods Sold Incl. D&A17290——————
Gross Profit504629——————
Selling, General and Administrative Excl. Other657785——————
Research and Development198187167——————
Other Operating Expense12-192——————
Operating Income-226-217-315——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)2940114——————
Net Income Before Taxes-197-178-200——————
Income Taxes-33-31-38——————
Consolidated Net Income-164-146-163——————
Net Income From Continuing Operations-164-146-163——————
Net Income-164-146-163——————
EPS (Recurring)-0.54-0.49-0.55——————
EPS (Basic, Before Extraordinaries)-0.54-0.49-0.55——————
EPS (Diluted)-0.54-0.49-0.55——————
EBITDA-161-149-204——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio42.6813.6329.70——————
Gross Margin75.7661.33100.00——————
Operating Margin-342.42-289.33-1,086.21——————
Net Margin-248.48-194.67-562.07——————
Shares Outstanding306299294——————
Market Capitalization2,8171,023861——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.03$7.05$5.07$3.09$1.11● Close Price0.00K214.17K428.35K642.52K856.70KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Montalbano John S.DirectorMay 14 '26Buy4.7720,00095,400241,000May 18
Thermopylae Holdings Ltd.10% OwnerFeb 27 '26Buy3.4438,000130,72056,134,097Mar 02
Booth AndrewChief Financial OfficerFeb 27 '26Buy3.4242,600145,692195,600Feb 27
Thermopylae Holdings Ltd.10% OwnerFeb 26 '26Buy3.27177,457580,28456,096,097Feb 27
Montalbano John S.DirectorNov 26 '25Buy3.5750,000178,460221,000Nov 26
Thermopylae Holdings Ltd.10% OwnerMar 11 '25Buy2.16343,631742,24356,143,640Mar 11
Montalbano John S.DirectorMar 10 '25Buy2.3025,00057,500171,000Mar 10
Montalbano John S.DirectorMar 06 '25Buy2.3460,000140,568146,000Mar 07
Hansen Carl L. G.Chief Executive OfficerNov 25 '24Option Exercise2.7056,125151,538898,000Nov 26
Hansen Carl L. G.Chief Executive OfficerSep 20 '24Option Exercise2.7056,125151,538841,875Sep 24
Thermopylae Holdings Ltd.10% OwnerAug 29 '24Buy2.61283,516739,97756,086,009Aug 29
Lecault VeroniqueChief Operating OfficerJun 21 '24Option Exercise0.1983,33415,6672,123,456Jun 24
Hansen Carl L. G.Chief Executive OfficerMay 31 '24Option Exercise2.7056,125151,538785,750Jun 03
Hansen Carl L. G.Chief Executive OfficerFeb 26 '24Option Exercise2.7056,125151,538729,625Feb 27
Hansen Carl L. G.Chief Executive OfficerNov 23 '23Option Exercise2.7056,125151,538673,500Nov 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.